title: Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network.
abstract: OBJECTIVE
  The aim of this study was to assess the outcome in patients with cerebellar glioblastoma (GBM) treated in 15 institutions of the Rare Cancer Network.
  
  
  METHODS
  Data from a series of 45 adult patients with cerebellar GBM were collected in a retrospective multicenter study. Median age was 50.3 years. Brainstem invasion was observed in 9 (20%) patients. Radiotherapy (RT) was administered to 36 patients (with concomitant chemotherapy, 7 patients). Adjuvant chemotherapy after RT was administered in 8 patients. Median RT dose was 59.4 Gy. Median follow-up was 7.2 months (range, 3.4-39.0).
  
  
  RESULTS
  The 1-year and 2-year actuarial overall survival rate was 37.8% and 14.7%, respectively, and was significantly influenced by salvage treatment (p = 0.048), tumor volume (p = 0.044), extent of neurosurgical resection (p = 0.019), brainstem invasion (p = 0.0013), additional treatment after surgery (p < 0.001), and completion of the initial treatment (p < 0.001) on univariate analysis. All patients experienced local progression: 8 and 22 had progression with and without a distant failure, respectively. The 1- and 2-year actuarial progression free survival was 25% and 10.7%, respectively, and was significantly influenced by brainstem invasion (p = 0.002), additional treatment after surgery (p = 0.0016), and completion of the initial treatment (p < 0.001). On multivariate analysis, survival was negatively influenced by the extent of surgery (p = 0.03) and brainstem invasion (p = 0.02).
  
  
  CONCLUSIONS
  In this multicenter retrospective study, the observed pattern of failure was local in all cases, but approximately 1 patient of 4 presented with an extracerebellar component. Brainstem invasion was observed in a substantial number of patients and was an adverse prognostic factor.
authors.affiliation: University Hospital of Geneva, Geneva, Switzerland. damien.weber@hcuge.ch
authors.forename: Damien C
authors.initials: DC
authors.lastname: Weber
authors.forename: Robert C
authors.initials: RC
authors.lastname: Miller
authors.forename: Salvador
authors.initials: S
authors.lastname: Villà
authors.forename: Patrick
authors.initials: P
authors.lastname: Hanssens
authors.forename: Brigitta G
authors.initials: BG
authors.lastname: Baumert
authors.forename: Pierre
authors.initials: P
authors.lastname: Castadot
authors.forename: Pascale
authors.initials: P
authors.lastname: Varlet
authors.forename: Ufuk
authors.initials: U
authors.lastname: Abacioglu
authors.forename: Sefik
authors.initials: S
authors.lastname: Igdem
authors.forename: Ewa
authors.initials: E
authors.lastname: Szutowicz
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nishioka
authors.forename: Silvia
authors.initials: S
authors.lastname: Hofer
authors.forename: Hans Peter
authors.initials: HP
authors.lastname: Rutz
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
authors.forename: Alphonse
authors.initials: A
authors.lastname: Taghian
authors.forename: René O
authors.initials: RO
authors.lastname: Mirimanoff
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002528:Cerebellar Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy / Q000379:methods; D018450:Disease Progression; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D035583:Rare Diseases / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome